PeptideStack
5.2kquestions
20kanswers
220users

My survodutide vial sat at 37 °C for twenty-one days — is testing worth it before use?

Asked 19 Dec 2024Modified 16 months agoViewed 52k times
33

Concretely: survodutide · 37 °C · twenty-one days.

The failure mode I am trying to avoid is making this decision emotionally.

I have twelve months in view and I would like the plan to survive that long.

How would you structure this, and what thresholds would you set in advance?

cold-chain
cold-chain

Keeping material within a temperature window from manufacture to use: phase-change packs versus dry ice, thermal mass, transit-lane temperature…

578 questions
peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questions
survodutide
survodutide

A GLP-1 and glucagon receptor dual agonist with a substantial published MASH dataset. Use this tag for its hepatic endpoints, its dose ladder, and…

225 questions
shareeditfollowflag
TH
askedthreadlock719k2819 Dec 2024

5 Answers

Sorted by votes
23

Twenty-one days at 37 °C is about 193 refrigerated days of equivalent exposure. 37 °C is 32 kelvin above the 5 °C middle of a 2–8 °C refrigerator. The ten-degree rule of thumb — degradation rate roughly doubling per 10 K — makes that about 9.2 times the refrigerated rate, which is an order-of-magnitude statement and not a shelf life. At 193 equivalent days you are outside what the original certificate speaks to, and a content assay is the test that changes your arithmetic — purity can look untouched while the milligrams have moved. Either way, record the twenty-one days and the temperature now, while you still know them; an excursion you did not write down is an excursion you cannot interpret later.

Answering this needs the transit duration and the ambient temperature, and then the arithmetic is straightforward.

Once the parcel arrives, the domestic leg is the controllable part: get it into the refrigerator promptly rather than leaving it in a warm hallway for a day.

It helps to be literal here: anything shipped in solution is a different risk category, because hydrolysis and deamidation proceed in the aqueous phase and are strongly temperature-dependent.

Nothing here is medical advice, and research-use compounds are not approved for human use.

A liquefied pack is expected. It is not evidence of a problem.

shareimprove this answerflag
HN
answeredhalvard_ness69k4717 Feb 2025
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
15

Answer first: for a lyophilised solid the cold chain matters far less than people believe, and for a solution it matters far more than they act as though it does.

A pack that arrived hard tells you about the last day of transit only, since it will have melted and, if the ambient dropped, partially refrozen.

A single phase-change pack in a thin-walled box holds below ten degrees for roughly one to two days at twenty-five degrees ambient, and under a day at thirty-five. On a nine-to-fourteen-day lane the material is at ambient for most of the journey whatever was packed with it.

Single-use temperature loggers are standard practice in supply chains where temperature genuinely matters and are inexpensive at parcel scale.

The domestic leg is the part you control. Refrigerate it promptly.

shareimprove this answerflag
RS
answeredrota_site36k2728 Feb 2025
Two lots stored differently, reassayed at a year — the difference was smaller than I expected. – Dr_Sara_Kuusela 9 months ago
add a comment
10

If temperature history matters to you, buy a data logger. It is the only way to know.

That is the argument for shipping lyophilised rather than for shipping colder. A dry powder with low residual moisture is stable at ambient for months; the pathways that matter need water.

It helps to be literal here: arrhenius behaviour means the degradation rate roughly doubles per ten degrees. A week at thirty degrees is therefore a meaningful exposure for a solution and an immaterial one for a dry solid.

Phase-change pack hold time is a function of mass, latent heat and insulation, and published figures for small parcels are on the order of one to two days.

Solutions are a different question and deserve the worry the solids get.

shareimprove this answerflag
DV
answeredDr_Bram_Verhoeven84k24826 Jan 2025
7

This is where the anxiety in this hobby is most out of proportion to the chemistry.

Asking a supplier to hold a shipment during a heatwave is reasonable and the better ones agree; the cost is a week and the benefit is a shorter warm exposure for anything in solution.

Arrhenius kinetics predict approximately a doubling of degradation rate per ten-degree rise and are the standard basis for cold-chain design.

Reconstituted material has a genuine cold-chain requirement and it starts the moment water is added.

Buy a logger if you actually want to know. Everything else is inference.

shareimprove this answerflag
KS
answeredk_szabo27k276 Feb 2025
6

The relevant physics is latent heat: a phase-change pack holds temperature only while it is changing phase, and once it has melted it is a warm mass.

A single-use temperature logger costs a few pounds, records the whole journey and converts an argument into a record. If the history matters, this is the answer.

Solid-state stability of lyophilised peptides at ambient temperature is documented in formulation studies with residual moisture as the dominant variable.

Lyophilised tolerates the lane. That is the answer for almost every order.

shareimprove this answerflag
DR
answeredDr_Priya_Raghunathan49k1372 Apr 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.